Bortezomib Booms For Stada As Russian Problem Remains

Turnaround Strategy Is In The Works In Russia

With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.

Rock_Climber_Greece
Stada's sales climbed by 12% in 2019 following the bortezomib launch • Source: Shutterstock

Stada has welcomed “an exceptionally successful financial year” for 2019, with double-digit sales growth largely driven by the successful launch of a ready-to-use, differentiated formulation of Janssen’s Velcade (bortezomib) in 14 European countries midway through the second quarter.

The German firm “broadly outperformed its competitors and achieved substantial market-share gains in almost all of its core markets during...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business